Compare AEYE & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | QTTB |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.9M | 80.0M |
| IPO Year | 2011 | 2018 |
| Metric | AEYE | QTTB |
|---|---|---|
| Price | $7.16 | $5.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.63 | $13.00 |
| AVG Volume (30 Days) | 174.1K | ★ 306.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.56 | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | $40,311,000.00 | ★ $53,737,000.00 |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $11.45 | N/A |
| P/E Ratio | ★ N/A | $2.37 |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $5.31 | $1.40 |
| 52 Week High | $16.39 | $8.05 |
| Indicator | AEYE | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 45.44 |
| Support Level | $6.35 | $5.51 |
| Resistance Level | $7.42 | $7.69 |
| Average True Range (ATR) | 0.38 | 0.64 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 81.09 | 30.49 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).